The ocular protection index

Cornea

Volumn 27, Issue 5, 2008, Pages 509-513

  Ousler III, George W ^a,b   Hagberg, Katrina Wilcox ^a   Schindelar, Michael ^a   Welch, Donna ^a   Abelson, Mark B ^a  

^a Ophthalmic Research Associates   (United States)

^b ORA Clinical Research and Development   (United States)

Author keywords

Blink rate; Clinical trials; Dry eye; Interblink interval; Keratoconjunctivitis sicca; Ocular Protection Index; Tear film breakup time

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; MUSCLE RELAXANT AGENT; PSYCHOTROPIC AGENT;

CALCULATION; COGNITION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRY EYE; EMOTION; ENVIRONMENTAL FACTOR; EYE DISCOMFORT; EYE PROTECTION; EYE PROTECTION INDEX; EYELID REFLEX; HUMAN; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; TASK PERFORMANCE; TEAR FILM; VISUAL STIMULATION; VISUAL SYSTEM EXAMINATION; BIOLOGICAL MODEL; BLINKING; CHEMISTRY; LACRIMAL FLUID; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

BLINKING; DRY EYE SYNDROMES; HUMANS; MODELS, BIOLOGICAL; TEARS;

EID: 48249115209     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31816583f6     Document Type: Review

References (54)

1. Mishima S, Gasset A, Klyce SD, et al. Determination of tear volume and tear flow. Invest Ophthalmol. 1966;5:264-275.
2. Abdul-Fattah AM, Bhrgva HN, Korb DR, et al. Quantitative in vitro comparison of fluorescein delivery to the eye via impregnated strip and volumetric techniques. Invest Ophthalmol Vis Sci. 1999;40(Suppl): S544.
3. Marquardt R, Stodtmeiser R, Christ T. Modification of tear film break-up time test for increased reliability. In: Holly FJ, ed. The Preocular Tear Film in Health, Disease and Contact Lens Wear. Lubbock, TX: Dry Eye Institute; 1986:57-63.
4. Abelson MB, Ousler GW III, Nally LA, et al. Alternative reference values for tear film break-up time in normal and dry eye populations. Cornea. 2000;19:S72.
5. Nally L, Ousler GW, Abelson MB. Ocular discomfort and tear film break-up time in dry eye patients. Invest Ophthalmol Vis Sci. 2000;41(Suppl):1436.
6. Abelson MB, Langelier N. A blueprint for your own dry-eye clinic. Rev Ophthalmol. 2006;13:110-113.
7. Ousler GW, Emory TB, Welch D, Abelson MB. Factors that influence inter-blink interval (IBI) as measured by the ocular protection index (OPI). Invest Ophthalmol Vis Sci. 2002;43(Suppl):56.
8. Ousler GW, Gomes PJ, Welch D, et al. Methodologies for the study of ocular surface disease. Ocular Surf. 2005;3:143-154.
9. Crampton J, Abelson MB, Ousler GW III, etal. Correlation of the controlled adverse environment (CAE) model with a murine model of experimental dry eye in assessing the ability of topical doxycycline to prevent corneal barrier disruption. Invest Opthalmol Vis Sci. 2007;48:402.
10. Kellerman DJ, Ousler GW, Abelson MB, et al. Placebo-controlled evaluation of diquafosol in a controlled adverse environment (CAE). Invest Ophthalmol Vis Sci. 2004;45:3892.
11. Ousler GW, Haque R, Weichselberger A, et al. Comparison of pimecrolimus 1%, 0.3% and 0.1% with vehicle for treatment of dry eye in the controlled adverse environment (CAE) model. Invest Ophthalmol Vis Sci. 2004;45:2031.
12. Ousler GW, Welch DW, Abelson MB. Effect of menopause on blink rate in a population of dry eye patients when exposed to a controlled adverse environment (CAE). Invest Ophthalmol Vis Sci. 2004;45:80.
13. Casavant J, Ousler GW, Abelson MB. Effect of an adverse environment on blink rate in a population of dry eye patients. Invest Ophthalmol Vis Sci. 2004;45(Suppl):77.
14. Doughty MJ. Consideration of three types of spontaneous eyeblink activity in normal humans: during reading and video display terminal use, in primary gaze, and while in conversation. Optom Vis Sci. 2001;78:712-725.
15. Karson CN, Berman KF, Donnelly EF, et al. Speaking, thinking, and blinking. Psychiatry Res. 1981;5:243-246.
16. Patel S, Henderson R, Bradley L, et al. Effect of visual display unit use on blink rate and tear stability. Optom Vis Sci. 1991;68:888-892.
17. Hall A. The origin and purpose of blinking. Br J Ophthalmol. 1945;29: 445-467.
18. Fogarty C, Stern JA. Eye movements and blinks: their relationship to higher cognitive processes. Int J Psychophysiol. 1989;8:35-42.
19. Orchard LN, Stern JA. Blinks as an index of cognitive activity during reading. Integr Physiol Behav Sci. 1991;26:108-116.
20. Sotoyama M, Villanueva MBG, Jonai H, et al. Ocular surface area as an informative index of visual ergonomics. Ind Health. 1995;33:43-56.
21. Nakamori K, Odawara M, Nakajima T, et al. Blinking is controlled primarily by ocular surface conditions. Am J Ophthalmol. 1997;124: 24-30.
22. Sheedy JE, Gowrisankaran S, Hayes JR. Blink rate decreases with eyelid squint. Optom Vis Sci. 2005;82:905-911.
23. Ponder E, Kennedy WP. On the act of blinking. Q J Exp Physiol. 1928;18: 89-119.
24. Fukada K. Eye blinks: new indices for the detection of deception. Int J Psychophys. 2001;40:239-245.
25. Holland MK, Tarlow G. Blinking and thinking. Percept Mot Skills. 1975;41:403-406.
26. Karson CN. Physiology of normal and abnormal blinking. Adv Neurol. 1988;49:25-37.
27. Karson CN. Spontaneous eye-blink rates and dopaminergic systems. Brain. 1983;106:643-653.
28. Yamaguchi M, Tokuyama T, Ikeda T, et al. Decrease in blinking in patients with diabetes. Invest Ophthalmol Vis Sci. 2000;41(Suppl):1429.
29. Clauser L, GalièM, Sarti E, et al. Rationale of treatment in Graves ophthalmopathy. Plast Reconstr Surg. 2001;108:1880-1894.
30. Tsubota K, Seiichiro H, Okusawa Y, et al. Quantitative videographic analysis of blinking in normal subjects and patients with dry eye. Arch Ophthalmol. 1996;114:715-720.
31. Collins M, Seeto R, Campbell L, et al. Blinking and corneal sensitivity. Acta Ophthalmol. 1989;67:525-531.
32. Yap M. Tear break-up time is related to blink frequency. Acta Ophthalmol. 1991;69:92-94.
33. Nally L, Ousler GW, Emory TB, et al. A correlation between blink rate and corneal sensitivity in a dry eye population. Invest Ophthalmol Vis Sci. 2003;44(Suppl):2488.
34. Brewitt H, Sistani F. Dry eye disease: the scale of the problem. Surv Ophthalmol. 2001;45:199-201.
35. Craig JP, Tomilinson A. Age and gender effects on the normal tear film. Adv Exp Med Biol. 1998;483:411-415.
36. Schaumberg DA, Sullivan DA, Buring JE, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136: 318-326.
37. Schaumberg DA, Sullivan DA, Dana MR. Epidemiology of dry eye syndrome. Adv Exp Med Biol. 2002;506:989-998.
38. Sullivan D. Sex and sex steroid influences on dry eye syndrome. In: Pflugfelder S, Beuerman RW, Stern ME, eds. Dry Eye and Ocular Surface Disorders. New York: Marcel Dekker, Inc.;2004:165-190.
39. Bron AJ. The contribution of meibomian disease to dry eye. Ocular Surf. 2004;2:149-165.
40. Calabria G, Rolando M. Definition and classification of dry eye syndromes. In: Calabria G, Rolando M, eds. Il Film Lacrimale. Milan: Fogliazza Editore;1997:163-182.
41. Grant K, Abelson MB, George MA, et al. Metaplastic changes to the lid margin epithelium - a contributing factor in dry eye syndrome. Invest Ophthalmol Vis Sci. 1998;39(Suppl):S538.
42. Bron AJ, Tiffany JM. The meibomian glands and tear film lipids. In: Sullivan DA, Dartt DA, Meneray MA, eds. Lacrimal Gland, Tear Film, and Dry Eye Syndromes 2. New York: Plenum Press;1998:281-295.
43. Krenzer KL, Dana MR, Ullman MD, et al. Effect of androgen deficiency on the human meibomian gland and ocular surface. Clin Endocrinol Metab. 2000;85:4874-4882.
44. Bron AJ. Non-Sjögren's dry eye: pathogenesis, diagnosis and animal models. In: Sullivan DA, ed. Lacrimal Gland, Tear Film and Dry Eye Syndromes. New York: Plenum Press;1994:471-488.
45. Argüeso P, Balaram M, Spurr-Michaud S, et al. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjögren syndrome. Invest Ophthalmol Vis Sci. 2002;43:1004-1011.
46. Crandall DC, Leopold IH. The influence of systemic drugs on tear film constitutes. Ophthalmology. 1979;86:115-125.
47. Polak BCP. Side effects of drugs and tear secretion. Documenta Ophthalmol. 1987;67:115-117.
48. Jaanus SD. Ocular side effects of selected systemic drugs. Optom Clin. 1992;2:73-96.
49. Katzung BG. Basic and Clinical Pharmacology. Stamford: Appleton & Lange 1998.
50. Welch D, Ousler GW, Nally L, et al. Ocular drying associated with oral antihistamines (loratadine) in the normal population-an evaluation of exaggerated dose effect. In: Sullivan DA, Stern ME, Tsubota K, et al, eds. Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3. New York: Kluwer Academic/Plenum Publishers;2002:1051-1055.
51. Ousler GW, Wilcox KA, Gupta G, et al. An evaluation of the ocular drying effects of 2 systemic antihistamines: loratadine and cetirizine hydrochlo-ride. Ann Allergy Asthma Immunol. 2004;93:460-464.
52. Davis J, Ousler GW, Langelier NA, et al. Seasonal changes in dry eye symptomatology. Invest Ophthalmol Vis Sci. 2006;47(Suppl):280.
53. Ousler GW, Abelson MB, Nally LA, et al. Evaluation of the time to ''natural compensation'' in normal and dry eye subject populations during exposure to a controlled adverse environment. In: Sullivan DA, Stern ME, Tsubota K, et al, eds. Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3. New York: Kluwer Academic/Plenum Publishers;2002:1057-1063.
54. Ousler GW, Michaelson C, Christensen MT. An evaluation of tear film break-up time extension and ocular protection index scores between three marketed lubricant eye drops. Cornea. 2007;26:949-952.